Fig. 4: FBXO22 promotes tumor growth in vivo.
From: Fbxo22 promotes cervical cancer progression via targeting p57Kip2 for ubiquitination and degradation
A Female nude mice were inoculated subcutaneously with SiHa control cells (shCtr) FBXO22 knockdown cells (shR2) (2 × 106 cells per mouse and the experiment lasted 6 weeks). The photographs of dissected tumors are presented. B, C Tumor growth curve (B) and terminal tumor weights (C) in the mice are presented as means ± SEM (N = 10). ***P < 0.001. D Female nude mice were inoculated subcutaneously with SiHa control cells (EV) and FBXO22 overexpressing cells (OE) (2 × 106 cells per mouse and the experiment lasted 6 weeks). The photographs of dissected tumors are presented. E, F Tumor growth curve (E) and terminal tumor weights (F) in the mice are presented as means ± SEM (N = 10). ***P < 0.001. G, H Representative images of IHC staining with anti-FBXO22 and anti-Ki67 antibodies in tumor tissues (×200, magnification). shCtr: control shRNA. shR2: FBXO22 knockdown with shR2. EV: empty vector, OE: FBXO22 overexpression.
